Support for Industry Focus comes from our friends at Rocket Mortgage by Quicken Loans.

Home plays a big role in your life.

That's why Quicken Loans created Rocket Mortgage.

It lets you apply simply and understand the entire mortgage

process fully so you can be confident that you're getting the right mortgage

for you. To get started go to rocket mortgage.com slash fool.

Welcome to Industry Focus, the podcast that dives into a different sector of the stock market every day.

It's Wednesday, October 10th. I'm your host Christine Harajus, and I'm joined today by my esteemed colleague and good friend, health care analyst Michael Douglas

welcome back to the show Michael. Thanks Christine it's great to be back I am very

excited to have you here with me today we have two topics on deck the first

one relates to biosimilars and the second one is about a new drug

approval for a company called Flection Therapeutics, which we will get to after we first cover

biosimilars. Do you want to kick us off with that first topic,

Michael? Sure, so it's a long story, but basically...

So settle in. Yeah, exactly. This is going to be a long episode. Now, Teva Pharmaceuticals has a drug called

Copaxone. It is the market share leader in multiple sclerosis. It is very popular and pretty expensive and it makes Tava a lot of money about 4 billion dollars a year.

Now, COBACSona is about 20% of TAVA's sales, but because it's such a high margin drug, it actually makes up a much bigger percentage of their

overall profit.

Copaxone is formulated in both 20 milligram and 40 milligram doses.

Now the 20 milligram dose basically meant once per day dosing and Teva

moved over to the 40 milligram dose once the patents for the 20 milligram dose expired, allowing generic competition to come in.

And so essentially what they did was they took this drug that could be dosed once a day and

...